8月20日，药明合联开盘上涨4.04%，报70.8港元/股，成交额477.9万港元。
消息面上，公司近日宣布新加坡基地BCM3双功能产线成功完成GMP放行，标志全球产能布局迈入新阶段，将与无锡基地BCM1、BCM2协同实现产能跃升，制剂线DP4亦将于8月底完成放行。此外，公司将于8月24日召开董事会审议中期业绩，同属"药明系"的药明康德上半年营收同比增38.93%、归母净利增29.43%并全面上调指引，提振板块预期。机构面上，里昂上调目标价至82.6港元，大和首予"买入"评级、目标价78港元。当日生命科学工具和服务板块延续强势，金斯瑞生物科技涨13.01%，药明生物涨7.52%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.